Pexelizumab and its role in the treatment of myocardial infarction and in coronary artery bypass graft surgery: A review

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 2, 2008, Pages 145-152

  Patel, Jagruti A ^a   Ghatak, Somsuvra B ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

Acute myocardial infarction; Anti C5 complement antibody; Coronary artery bypass graft surgery; Monoclonal antibody; Pexelizumab

Indexed keywords

COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; FIBRINOLYTIC AGENT; HEART ENZYME; MONOCLONAL ANTIBODY; PEXELIZUMAB; PLACEBO; ANTIINFLAMMATORY AGENT; CARDIOVASCULAR AGENT; H5G1.1 SCFV; H5G1.1-SCFV;

ANEMIA; ANTIBODY ENGINEERING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CORONARY ARTERY BYPASS SURGERY; DEATH; DRUG HALF LIFE; ENZYME RELEASE; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART RUPTURE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MORTALITY; NAUSEA; OPEN HEART SURGERY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE COMPLICATION; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REPERFUSION INJURY; RESPIRATORY FAILURE; REVIEW; SEPSIS; STROKE; THORAX PAIN; TISSUE INJURY; WOUND INFECTION; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; IMMUNOLOGY; PATENT; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CARDIOPULMONARY BYPASS; CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; COMPLEMENT ACTIVATION; CORONARY ARTERY BYPASS; HUMANS; MYOCARDIAL INFARCTION; PATENTS AS TOPIC; TREATMENT OUTCOME;

EID: 51149117632     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008784705322     Document Type: Review

References (46)

1. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481-3488.
2. Bhole D, Stahl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med 2003; 31: S97-S104.
3. Gupta-Bansal R, Parent JB, Brunden KR. Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Mol Immunol 2000; 37(5): 191-201.
4. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995; 91: 393-402.
5. Amsterdam EA, Stahl GL, Pan HL. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 1995; 268: H448-H457.
6. Riedemano NC, Ward PA. Complement in ischemia reperfusion injury. American J Pathol 2003; 162(2): 363-367.
7. Vakeva AP, Aga A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: Role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97: 2259-2267.
8. De Zwaan C, Kleine AH, Diris JH. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002; 23: 1670-1677.
9. Speidl WS, Exner M, Amighi J, et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 2005; 26(21): 2294-2299.
10. Procter LM, Woodruff TM, Taylor SM. Recent developments in C5/C5a inhibitors. Expert Opin Ther Pat 2006; 16(4): 445-458.
11. Pexelizumab being invested to reduce perioperative mortality in patients undergoing CABG-CPB surgery. August11,2005; 1: Http://www.rxpgnews.com/ surgery/ctvs/article.
12. Piribo online Business intelligence for the biopharma industry. http://www.piribo.com
13. Bonvini RF, Hendiri T, Camenzind E. Inflammatory response post myocardial infarction and reperfusion: A new therapeutic target? Eur Heart J 2005; 7(1): 127-136.
14. Thomas TC, Rollins SA, Rother RP. Inhibition of complement activity by humanized anti-C5 antibody and single chain Fv. Mol Immunol 1996; 33(17/ 18): 1389-1401.
15. Langlois PF, Gawryl MS. Detection of the terminal complement complex in patient's plasma following acute myocardial infarction. Atherosclerosis 1988; 70: 95-105.
16. Griselli M, Herbert J, Hutchinson WL. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190: 1733-1740.
17. Lagrand WK, Niessen HW, Wolbink GJ. C-reactive protein co-localizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95: 97-103.
18. Beranek JT. C-reactive protein and complement in myocardial infarction and post-infarction heart failure. Eur Heart J 1997; 18: 1834-1836.
19. Mathey D, Schofer J, Schafer HJ. Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur Heart J 1994; 15: 418-423.
20. Frangi D, Gardinali M, Coniciato L. Abrupt complement activation and transient neutropenia in patients with acute myocardial infarction treated with streptokinase. Circulation 1994; 89: 76-80.
21. Beranek JT. Why primary Angioplasty is less offensive to the myocardium compared with thrombolysis for acute myocardial infarction. Am Heart J 2000; 140: E5.
22. Armstrong PW, Mahaffey KW, Wei-Ching C, et al. Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. Am Heart J 2006; 151(4): 787-790.
23. Fitch JC, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999; 100: 2499-2506.
24. Kevin NG, Liu H, Maslow A. Pexelizumab: Complement inhibition for the cardiac patient? Society of Cardiovascular Anesthesiologists 2004; 1-4.
25. Mahaffey KW, Granger CB, Nicolau JC, COMPLY Investigators. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003; 108: 1176-1183.
26. Granger CB, Mahaffey KW, Weaver WD, COMMA Investigators. Pexelizumab, an Anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction -The COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Circulation 2003; 108: 1184-1190.
27. Framgpgoammos MG, Sotj CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
28. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation 2003; 107: 2998-3002.
29. Anazai T, Yoshilawa T, Shiraki H. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997; 96: 778-784.
30. Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: Effects of an early invasive or noninvasive strategy. JAMA 2001; 286: 2107-2113.
31. Theroux P, Armstrong PW, Mahaffey KW, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: A substudy of the COMMA trial. Eur Heart J 2005; 26: 1964-1970.
32. Verrier ED, Shernan SK, Taylor KM, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass -a randomized trial. JAMA 2004; 291(19): 2319-2327.
33. Armstrong PW, Granger CB, Adams PX, APEX AMI investigators. pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention- a randomized controlled trial. JAMA 2007; 297(1): 43-51.
34. Smith PK, Levy JH, Shernan SK. Pexelizumab, a terminal complement inhibitor in coronary artery bypass graft surgery: Results from the pexelizumab for the reduction in myocardial infarction and mortality in CABG II trial. In: Programme and abstracts of the 55th Annual American College of Cardiology Scientific Session; March 11-14, 2006; Atlanta, Ga. Abstract 411-412.
35. Gruberg L. PRIMO-CABG II: Pexelizumab for the reduction of the infarction and mortality in Coronery Artery Bypass Graft Surgery II. http://www.medscape.com/viewarticle/529650.
36. O'Riordan M. PRIMO-CABG II: Pexelizumab fails to reduce death or MI after cardiac surgery. http://www.theheart.org/article/672281.do.
37. Armstrong PW, Granger CB. Reflections on early stopping of a clinical trial. Am Heart J 2006; 152: 407-409.
38. Armstrong PW, Granger CB. Pexelizumab and the APEX AMI Trial. JAMA 2007: 297(17): 1881-1882.
39. Eikelboom JW, O'Donnell M. Pexelizumab does not "Complement" percutaneous coronary intervention in patients with ST-elevation Myocardial infarction. JAMA 2007; 297(1): 91-92.
40. Tjandrawidjaja MC, Fu Y, Al-Khalidi H, et al. Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: Lessons from APEX-AMI. Eur Heart J 2007; 28(23): 2850-2857.
41. Mathew JP, Shernan SK, White WD, et al. Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. Stroke 2004; 35: 2335-2339.
42. Todaro, T.G., Malloy, K.J.: WO06125200 (2006).
43. Epstein, D., Kurz, J.C.: WO07103549 (2007).
44. Rother, R.P., Wang, H.C., Zhong, Z.: WO07103134 (2007).
45. Bornancin, F., Oberhauser, B.: WO07112914 (2007).
46. Schnatbaum, K., Scharn, D., Locardi, E., Polakowski, T., Richter, U., Reineke, U, Hummel, G.: WO06128670 (2006).